FDG-PET/CT performances to detect systemic sarcoidosis in patients from a general hospital in Europe
Conclusions: Our retrospective study shows that FDG PET/CT examination is a reliable method to detect systemic sarcoidosis (high sensibility, specificity, PPV, NPV and accuracy). However further evaluation of cost effectiveness of this examination, and a more comprehensive understanding on which patients would benefit from this intervention are warranted.
Rapid CommunicationRiley Hazard, Kyle B. Enfield, Darla J. Low, Eve T. Giannetta, Costi D. Sifri,Infection Control&Hospital Epidemiology,Volume 37 Issue 09, pp 1111-1113Abstract
The incidence of esophageal adenocarcinoma (EAC) is rising despite a better understanding of the natural history of Barrett ’s esophagus (BE) as a precursor lesion for EAC.1 Surveillance is recommended once the diagnosis of BE is established, and endoscopic eradication therapy is reserved for treatment of dysplasia or early neoplasia.2
Esophageal cancer is the eighth most common cancer worldwide and represents the sixth leading cause of global cancer mortality.1 Although esophageal adenocarcinoma (EAC) now accounts for the majority of esophageal cancer diagnosed in the United States, esophageal squamous cell carcinoma (ESCC) remains far more prevalent worldwide. The International Agency for Research on Cancer estimates that 88% of esophageal cancer cases in 2012 were ESCC, with only 12% representing EAC. ESCC exhibits a striking regional variation in incidence, both globally and within a single nation.
Esophageal adenocarcinoma (EAC) is highly lethal and is becoming more prevalent. Barrett ’s esophagus (BE) precedes some EACs. Screening for BE remains controversial. In this issue, Honing et al1 suggest that screening for BE with the use of ultrathin transnasal endoscopy with Endosheath (uTNE) in 50-year-old white men with chronic GERD symptoms is cost effective. How does a typical reader assess this modeling study?
CONCLUSION: In patients who weigh 100kg or less but are overweight or obese and do not present an adequate response with UST 45mg, increasing the dose to UST 90mg could be an alternative option. PMID: 30883242 [PubMed - as supplied by publisher]
CONCLUSIONS: EBUS-TBNA is a safe and efficacious procedure which can be performed using conscious sedation with high yields. It can be used for the staging of malignancies as well as for the diagnosis of inflammatory and infectious conditions such as sarcoidosis and TB.
Conclusions: EBUS-TBNA is highly accurate (diagnostic yield 92%) and safe procedure for diagnosing mediastinal lymphadenopathy. In our experience, granulomatous lymphadenitis was most common with TB as the main etiology.
Conclusions Lung biopsy through medical thoracoscopy is a safe, effective and viable procedure for the diagnosis of diffuse parenchymal lung diseases.
ConclusionThe operation risk of EBUS‐TBNA is relatively small. In diseases complicated by mediastinal lymphadenectasis, malignant diseases are most, and benign diseases mainly are granulomatous. EBUS‐TBNA is a valuable diagnostic technique in patients with mediastinal lymphadenectasis whose diagnosis have not been determined.
ConclusionThe operation risk of EBUS‐TBNA is relatively small. In the diseases complicated by mediastinal lymphadenectasis, malignant diseases are most, and benign diseases mainly are granulomatous. EBUS‐TBNA is a valuablediagnostic technique in patients with mediastinal lymphadenectasis whose diagnosis have not been determined.